Home Alzheimer’s Disease Efficacy With Enfortumab Vedotin for Cisplatin-Ineligible Urothelial Cancer Shows Unmatched Response Rates

Efficacy With Enfortumab Vedotin for Cisplatin-Ineligible Urothelial Cancer Shows Unmatched Response Rates

Response rates that have never been observed with any regimen for cisplatin-ineligible, locally advanced or metastatic urothelial cancer after prior PD-1/PD-L1 inhibitors were seen with the use of enfortumab vedotin (Padcev), according to results from the phase 2 EV-201 trial (NCT03219333) presented during the 2021 Genitourinary Cancers Symposium.1

EV-201 was a noncomparative study with 2 cohorts. Cohort 1 has been previously reported on and was the subject of accelerated approval by the FDA in December 2019.2

“What I’ll discuss today are data from cohort 2, which specifically focused on cisplatin-ineligible patients who received immunotherapy in the frontline setting, and who were ineligible for cisplatin-containing chemotherapy at the time of study enrollment,” Arjun V. Balar, MD, said during a presentation of the data.

Cisplatin-based chemotherapy is considered the standard of…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments